Sino Biopharmaceuticals Ltd.
Rm 4109, Office Tower
Convention Plaza, 1 Harbour Road
Wanchai
Hong Kong
Tel: 852-2802-9886
Fax: 852-2880-0847
Website: http://www.sinobiopharm.com/en/
Email: info@sino-biopharm.com
10 articles about Sino Biopharmaceuticals Ltd.
-
invoX Pharma Increases Investment in pHion Therapeutics to Further Develop Next Generation of mRNA Vaccines
6/1/2023
invoX Pharma Limited announced that it has completed a second tranche of investment in pHion Therapeutics, a next-generation mRNA vaccine company.
-
Inventiva announces that its partner Sino Biopharm received IND approval from the NMPA to initiate clinical trial with lanifibranor in China
5/25/2023
Inventiva and Sino Biopharm, through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd., announce that CTTQ received Investigational New Drug approval from the Chinese National Medical Products Administration on May 22nd 2023, and can now initiate the clinical development of Inventiva’s lead compound lanifibranor in mainland China.
-
invoX Pharma and F-star Therapeutics issue Joint Statement
1/26/2023
invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited, and F-star Therapeutics, Inc., issued the following statement regarding their pending transaction in response to a media report:
-
invoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical Programs
6/23/2022
InvoX Pharma (“invoX”), a wholly owned subsidiary of Sino Biopharmaceutical Limited and F-star Therapeutics, Inc. today announced that the companies have entered into a definitive agreement whereby invoX will acquire all of the issued and outstanding shares of F-star common stock for $7.12 per share.
-
Graviton Enters into Global Licensing Agreement for ROCK2 Inhibitor from Beijing Tide
2/23/2021
Founder Samuel D. Waksal, Ph.D., to lead Graviton in developing therapeutics in autoimmune diseases, various cancers, certain genetic diseases, fibrotic and other disorders for which there is current unmet medical need.
-
Genetron Health Announces Exclusive Strategic Partnership with Sino Biopharm Subsidiary for HCCscreen™ in China
1/6/2021
Chia Tai Tianqing Pharmaceutical Group Co. Ltd., a subsidiary of Sino Biopharm, has a leading liver drug franchise with a major presence in liver disease hospitals in China
-
Ambrx and Sino Biopharma Announce Collaboration to Develop Two Next-Generation Biologics
1/13/2020
Ambrx Inc. and Sino Biopharmaceutical Limited announced a joint collaboration to develop two products enabled by Ambrx's unique non-natural amino acid incorporation technology platforms.
-
4 Biotechs Ready to Kill the Market in 2018
12/29/2017
A look at a few biotechs which should outperform the market in 2018. -
Johnson & Johnson In-Licenses Immune Adjuvant From Sino Biopharmaceuticals Ltd.
1/8/2016
-
Chinese Companies Gan & Lee Pharmaceuticals, Sino Biopharmaceuticals Ltd. Get Caught Up in Corruption Allegations
9/12/2013